# A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

> **NCT02809053** · PHASE3 · COMPLETED · sponsor: **Archigen Biotech Limited** · enrollment: 315 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **BIOLOGICAL:** SAIT101
- **BIOLOGICAL:** MabThera®

## Key facts

- **NCT ID:** NCT02809053
- **Lead sponsor:** Archigen Biotech Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-18
- **Primary completion:** 2019-07-17
- **Final completion:** 2020-01-10
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02809053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02809053, "A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02809053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*